Chan J S, Nie Z R, Seidah N G, Chrétien M
FEBS Lett. 1986 May 26;201(1):168-72. doi: 10.1016/0014-5793(86)80592-0.
In the radioreceptor assay for growth hormone (RRA-GH) using [125I]iodo-hGH, hGH and human liver membrane particulate fractions as tracer, hormone standard and receptors, respectively, ovine placental lactogen (oPL) is capable of inhibiting the binding of [125I]iodo-hGH in a parallel manner with hGH and in equipotency. Similarly, in the RRA-GH by employing [125I]iodo-oPL, oPL and human liver membrane particulate fractions as tracer, hormone standard and receptors, respectively, hGH is also equipotent as oPL in inhibiting the binding of [125I]iodo-oPL in a parallel fashion. The addition of monoclonal antibodies against oPL in the assay was effective in inhibiting the binding of [125I] iodo-oPL to human liver, but could not, however, inhibit the binding of [125I]iodo-hGH to human liver. Furthermore, the addition of the monoclonal antibodies in the RRA-GH did not affect the parallelism of the oPL standard but lowered the total binding of oPL. Our studies indicate that the structure of the binding sequence in oPL which binds to the GH receptor of human liver is not identical to the equivalent sequence of hGH and that the monoclonal antibodies compete with GH receptors in human liver for the binding of oPL.
在使用[125I]碘代人生长激素(hGH)、人生长激素(hGH)和人肝膜微粒体部分分别作为示踪剂、激素标准品和受体的生长激素放射受体分析(RRA - GH)中,绵羊胎盘催乳素(oPL)能够以与hGH平行且等效的方式抑制[125I]碘代hGH的结合。同样,在使用[125I]碘代oPL、oPL和人肝膜微粒体部分分别作为示踪剂、激素标准品和受体的RRA - GH中,hGH在以平行方式抑制[125I]碘代oPL的结合方面也与oPL等效。在分析中加入抗oPL单克隆抗体可有效抑制[125I]碘代oPL与人肝的结合,但却不能抑制[125I]碘代hGH与人肝的结合。此外,在RRA - GH中加入单克隆抗体并不影响oPL标准品的平行性,但降低了oPL的总结合量。我们的研究表明,oPL中与人类肝脏生长激素受体结合的结合序列结构与hGH的等效序列不同,并且单克隆抗体与人肝脏中的生长激素受体竞争oPL的结合。